Atezolizumab: First Global Approval.

Article Details

Citation

Copy to clipboard

Markham A

Atezolizumab: First Global Approval.

Drugs. 2016 Aug;76(12):1227-32. doi: 10.1007/s40265-016-0618-8.

PubMed ID

27412122 [ View in PubMed

]

Abstract

Atezolizumab (Tecentriq)-a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)-is being developed by Genentech as treatment for a variety of haematological malignancies and solid tumours. It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer. This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.

DrugBank Data that Cites this Article

Drugs

Atezolizumab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Atezolizumab	Programmed cell death 1 ligand 1	Protein	Humans	Yes	Inhibitor Antibody	Details